BioDuro, Atombeat Launch AI-Powered Platform for Accelerated Peptide Drug Discovery

BioDuro, a global CRDMO, and Atombeat Inc., a leading force in AI for drug discovery, entered a strategic collaboration to develop an AI-powered platform to accelerate peptide drug discovery.

This collaboration combines Atombeat’s in silico modeling expertise, AI-accelerated & data-driven design platform, with BioDuro’s expertise in discovery chemistry, biology, and DMPK to accelerate the development of next-generation peptides. 

Atombeat accelerates AI-driven drug discovery through its proprietary Hermite software and RiDYMO platform, enhanced by technologies such as Reinforced Dynamics, Uni-Dock, Uni-FEP, and Uni-QSAR. These technologies use advanced computer modeling, artificial intelligence, and specialized data to explore a digital library of over one trillion potential peptide compounds — built from more than 1000 natural and non-natural amino acids.

This exploration happens in silico, before any lab testing begins. The platform rapidly filters and prioritizes these compounds based on key developability traits such as membrane permeability. 

By enabling a seamless end-to-end workflow — from molecular design to preclinical candidate — this platform aims to deliver high-quality cyclic peptides with faster timelines and better economy across a broad range of therapeutic areas.

Once the design phase is complete, BioDuro leverages its high-throughput synthesis capability to produce hundreds of peptide compounds in parallel. In one week, the team could deliver high-purity peptides — ready for biological testing — without purification steps needed. 

“We are excited to advance peptide innovation through our strategic partnership with Atombeat,” said Dr. Armin Spura, CEO of BioDuro. “Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.”

Dr. Dongdong Wang, co-founder of Atombeat, commented, “By integrating AI with experimental processes, we are committed to building an intelligent, integrated platform for peptide drug discovery and evaluation. Our shared commitment is to drive innovation in pharmaceutical development and help meet unmet clinical needs worldwide.”